COVID-19 and catatonia: Prevalence, challenges, pathophysiology, and treatment.
Ann Clin Psychiatry
; 35(2): 118-130, 2023 05.
Article
en En
| MEDLINE
| ID: mdl-37074970
ABSTRACT
BACKGROUND:
Emerging literature supports the association between acute COVID-19 infection and neuropsychiatric complications. This article reviews the evidence for catatonia as a potential neuropsychiatric sequela of COVID-19 infection.METHODS:
PubMed was searched using the terms catatonia, severe acute respiratory syndrome coronavirus 2, and COVID-19. Articles were limited to those published in the English language between 2020 and 2022. Forty-five articles that specifically studied catatonia associated with acute COVID-19 infection were screened.RESULTS:
Overall, 30% of patients with severe COVID-19 infection developed psychiatric symptoms. We found 41 cases of COVID-19 and catatonia, with clinical presentations that varied in onset, duration, and severity. One death was reported in a case of catatonia. Cases were reported in patients with and without a known psychiatric history. Lorazepam was successfully used, along with electroconvulsive therapy, antipsychotics, and other treatments.CONCLUSIONS:
Greater recognition and treatment of catatonia in individuals with COVID-19 infection is warranted. Clinicians should be familiar with recognizing catatonia as a potential outcome of COVID-19 infection. Early detection and appropriate treatment are likely to lead to better outcomes.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Catatonia
/
Terapia Electroconvulsiva
/
COVID-19
/
Trastornos Mentales
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
/
Prevalence_studies
/
Risk_factors_studies
/
Screening_studies
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article